Gilead Sciences Inc (GILD): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Gilead ( GILD) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.6%. By the end of trading, Gilead fell $1.32 (-2.4%) to $54.48 on average volume. Throughout the day, 10,837,886 shares of Gilead exchanged hands as compared to its average daily volume of 11,995,400 shares. The stock ranged in price between $54.48-$56.21 after having opened the day at $56.21 as compared to the previous trading day's close of $55.80. Other companies within the Health Care sector that declined today were: Escalon Medical Corporation ( ESMC), down 12.5%, Bovie Medical Corporation ( BVX), down 11.7%, Astex Pharmaceuticals ( ASTX), down 10.2% and AMAG Pharmaceuticals ( AMAG), down 9.9%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $84.9 billion and is part of the drugs industry. The company has a P/E ratio of 31.1, above the S&P 500 P/E ratio of 17.7. Shares are up 51.5% year to date as of the close of trading on Thursday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, solid stock price performance, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, Affymax ( AFFY), down 32.5%, Uroplasty ( UPI), down 18.8%, MGC Diagnostics ( MGCD), down 12.9% and TherapeuticsMD ( TXMD), down 10.7% , were all gainers within the health care sector with Aegerion Pharmaceuticals ( AEGR) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Faster Rebuild After Harvey; Micron Tech Breakout Would Be a Win: Best of Cramer